Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.
News|Articles|September 29, 2026
GLP-1 Payment Risks: What Pharmacies Should Review with Their Processor
Author(s)Stephanie O'Connor
As more pharmacies dispense GLP-1s, payment processor reviews, higher fees and account closures are emerging as an overlooked point of friction in the access channel.
Advertisement
Advertisement
Eleven percent of U.S. adults report taking a GLP-1 drug in 2026, up from 3% in 2024.1 For pharmacies, meeting that demand may seem straightforward: a doctor writes a prescription, the pharmacy fills it, and the patient pays. But for payments, it’s not that simple.
Related to this article
Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.
Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Advertisement
Advertisement